TABLE I. Clinical features of treated patients.
| Patient ID | Age (years)/gender | Place of birth | BNZ dose (mg/kg/day) | BNZ treatment (days) | SatDNA and kDNA qPCRs | Adverse drug reactions |
|---|---|---|---|---|---|---|
| 1 | 45/M | Paraguay | 2.60 | 60 | ND/ND/ND | 10th day: mild dermatitis 53rd day: mild myalgia in lower limbs |
| 2 | 33/F | Argentina | 2.50 | 60 | NQ/ND/ND | 45th day: pruritus 24th day after EOT: cervical lymph node pain |
| 3 | 33/M | Argentina | 5.48 | 23 | ND/-/ND | 13th day: mild dermatitis 23rd day: oral mucositis, dysgeusia, and paresthesia in lower limbs |
| 4 | 29/F | Bolivia | 4.12 | 32 | ND/ND/- | 9th day: pruritus 26th day: liver enzymes 20 times UNL, hypereosinophilia |
| 5 | 21/M | Bolivia | 4.55 | 60 | NQ/ND/ND | Not observed |
| 6 | 31/M | Bolivia | 4.55 | 60 | NQ/ND/- | Not observed |
BNZ: benznidazole; EOT: end of treatment; F: female; M: male; ND: nondetectable; NQ: nonquantifiable (time of measurement: baseline/end of treatment/6 month of follow-up); qPCR: quantitative polymerase chain reaction; UNL: upper normal level.